An Economic Evaluation of the A(H1N1) Flu Vaccine in Mexico by Vargas-Palacios, Armando
APPENDICES 
Table of contents 
I. Characteristics of cost-effectiveness models for infectious diseases 159 
II. Brief theoretical background on compartmental models 162 
III. Brief theoretical background on Discrete event simulation models 164 
IV. Additional information relating the calibration of the ODE model 166 
V. Additional information regarding the CE of the vaccine intervention 173 
V.I Additional CE analysis graphs 175 
VI. Regional comparisons of methods to estimate the cost-effectiveness of vaccine interventions
 182 
VI.I Methodology 182 
VI.II Results 183 
VI.III Summary 195 
VII. Literature review search filters 196 
VII.I Search filters used to identify the papers to explore the Cost-effectiveness of infectious 
disease vaccine interventions 196 
VII.II Medline 197 
VII.III EMBASE 199 
VII.IV Econlit via Ovid 201 
VII.V CINAHL 203 
VII.VI Web of Knowledge 205 
VII.VII SCOPUS 206 
VII.VIII Filters for each specific analysed disease 208 






I. Characteristics of cost-effectiveness models for infectious diseases 
 
According to the NHS Economic Evaluation Database (NHS EED) “full economic 
evaluations are studies in which a comparison of two or more treatments or care 
alternatives are undertaken and in which both costs and outcomes of the alternatives 
are examined. This includes cost-benefit analyses, cost-utility analysis and cost-
effectiveness analyses” (Centre for Reviews and Dissemination, 2011).1 
Several methodological challenges need to be considered when developing a model to 
assess the CE of a vaccine robustly. One of the most relevant is how the cost-
effectiveness model simulates the transmission of the disease. 
The risk of infection that a person who is susceptible depends on the number of 
individuals in the population with the disease who can transmit it (referred to as 
infectious individuals) and how frequently they contact other individuals. This results in 
a constantly changing probability of the risk of infection with a non-linear transmission 
effect. This characteristic results in a crucial element: the herd immunity (HI) effect. The 
HI effect defined as “the indirect protection experienced by unvaccinated individuals 
resulting from the presence of immune individuals in a population” (Vynnycky and 
White, 2010). This phenomenon can modify the vaccine effectiveness in either a 
positive or negative manner.  
Widely used methodologies such as decision trees or Markov models assume that the 
risk of infection is constant or not dependent on the effective contact rate between 
susceptible and infectious individuals.2 Such models are commonly referred to as static 
models.  
Static models follow a linear transmissibility rate, which might produce bias results as 
the spread of the disease and HI effect are not correctly estimated (Brisson and 
Edmunds, 2006).  
The HI effect and its impact on the spread of infection are dependent on: the type of 
disease; the rate at which susceptible individuals become infected per unit time 
                                               
1 (Drummond et al., 2015) distinguishes between cost-effectiveness, cost-utility and cost-benefit analysis. 
By this distinction, the cost-effectiveness analysis measures the effects of the program in health outcomes; 
the cost-benefit analysis measures the effect of a program in monetary terms. Cost-utility is used when the 
outcome measure is weighted by utilities such as QALYs. For simplicity, the term cost-effectiveness used 
in this thesis incorporates cost-effectiveness, cost-benefit and cost-utility analyses. As described in 
Chapter 6, the cost-effectiveness analysis performed here follows a cost-utility approach since it measures 
the health outcomes in terms of QALYs. 




(defined as the force of infection); the extent of the vaccination program; and how well 
the vaccine prevents the circulation of the pathogen. HI can also produce a change in 
the distribution of age when infected. By this phenomenon, an increase or decrease in 
the mortality and morbidity in later ages can occur (Brisson and Edmunds, 2003). 
More complex models explicitly take the non-linear risk of infection over time into 
consideration often through interaction between individuals. Such models are 
commonly referred to as dynamic models. In a dynamic model, the risk of infection is 
assumed to be a function of the number of infectious individuals in the population at a 
given point in time, multiplied by the effective contact rate between susceptible and 
infectious individuals.  
Dynamic models provide a more realistic estimation of the spread of the disease. 
These type of models account for the potential HI effect produced by a vaccine 
intervention (Brisson and Edmunds, 2006). These models, however, can arguably be 
more difficult and time-consuming to implement. 
Kim and Goldie, (2008), suggested that most of the published literature on the topic is 
based on a static setting, this was corroborated by the results of the literature search 
performed in this thesis. It has been argued that using a static approach may 
underestimate the effectiveness of the vaccine and therefore if the vaccine intervention 
is deemed to be CE within a static models, the use of a more complex dynamic model 
would not change the decision ((Margolis et al., 1996), cited in (Edmunds et al., 1999)). 
However, as commented above, the HI effect does not always increase the 
effectiveness of the intervention (Brisson and Edmunds, 2003). Therefore the overall 
impact of HI is unknown.  
Whilst static and dynamic models can produce similar results when the vaccination 
program is small or where the vaccine does not effectively prevent the circulation of the 
pathogen, a dynamic model should be the preferred approach (Brisson and Edmunds, 
2003). However, in many circumstances, particularly historically, this was not possible 
due to the available resources, data availability or researcher proficiency. In such 
circumstances, a static model might be a helpful tool for decision-making.   
In general terms, a static model may be an acceptable choice when estimating a worst-
case scenario where the HI is not relevant or when all parameters are known. (Brisson 
and Edmunds, 2003; Vynnycky and White, 2010). The WHO suggests that a static 
approach is acceptable when: “human to human transmission is non-existent or 
exceptional; the vaccine does not reduce susceptibility to infection or infective 
transmission potential; the eligible target groups are not or do not include an 
epidemiologically influential subgroup (e.g.; elderly or travellers); where there are no 
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negative externalities from vaccination or these are very likely to be smaller than the 
positive.” If those elements are taken into consideration, and the static model shows 
favourable results for vaccination a static model is accepted (WHO 2008). 
According to the WHO choosing between static and dynamic models is the pivotal 
choice in infectious disease modelling when aiming to estimate the CE of a vaccine 
intervention (WHO, 2008).  
Both ODE and DES techniques are classified as dynamic models. However, a key 
difference between the two is how individuals are taken into consideration. The ODE 
method works on an aggregation of the population while DES tracks the progression of 
all or selected individuals in the model.3 
An aggregate-level model assigns individuals to compartments depending on their 
status. The movement between stages or compartments is based on average values. 
In contrast, individual level models keep track of individuals within the simulation. The 
movement between stages in individual level models can depend on the individual’s 
characteristics or previous history. The ODE model approach is part of the 
compartmental or System Dynamics (SD) technique. The SD technique is a continuous 
time, aggregate level method that models the relationship between elements in a 
system and how these influence its behaviour over time (more details are provided in 
Appendix II). The DES technique is a computer simulation approach. This approach is 
an individual level, continuous time model that employs a next event technique to 




                                               
3 Models classification depending on being static or dynamic and other characteristics has been 
discussed in Chapter 3 
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II. Brief theoretical background on compartmental models 
 
According to (Kim and Goldie, 2008), and the literature review performed here, the 
most commonly used technique to model the CE of an infectious disease vaccine 
intervention within dynamic models is compartmental models (classed as SD in the 
terminology of this thesis). Such models are usually set in continuous time setting 
(although discrete time models can also be performed).4 The structures of a system 
can be constructed based on difference, ordinary or partial differential equations to 
describe the rate of change of a particular state or condition (Brennan et al., 2006). 
Such types of models stratify the population into different subgroups or 
“compartments”. The models describe the transmission of the infection using the total 
number of individuals in each compartment.  Individuals move between 
“compartments” according to parameters values at the aggregate level (Kim and 
Goldie, 2008). In infectious disease models, these “compartments” usually refer to 
individuals who are susceptible, pre-infectious or latent, infectious and recovered. 
However, these compartments can be modified depending on the type of disease 
analysed.  For example, SI models track only susceptibles and infectious; SIS models: 
Susceptibles-infectious-susceptibles; SIR models: Susceptible-infectious-recovered; 
SIRS models: Susceptibles-infectious-recovered-susceptibles; and SEIR models: 
Susceptibles-pre-infectious or exposed-infectious-recovered. 
Models based on difference equations describe the transitions between different 
compartments using discrete time steps. The model determines the number of 
individuals in each compartment at time 𝑡 + 1 in terms of the number at time 𝑡. This 
approach offers some limitations since the size of the step can influence the model 
predictions, as the predicted epidemic curve becomes less smooth when the time steps 
increases. As the step size decreases the model tends towards resembling a 
continuous time model. The use of partial differential equations, however, allows the 
inclusion of another variable such as patient age. Partial differential equations can 
describe the spread of a disease in an age-structure population. 
The risk of infection also known as force of infection is one of the most relevant 
parameters of an infectious disease model. The force of infection 𝜆(𝑡) can be defined 
as the rate at which susceptible individuals become infected per unit time (Vynnycky 
and White, 2010). The force of infection is a function of two main parameters: the per-
                                               
4 A discrete time finite difference equation can be used using the Euler-forward approximation (Brennan et 
al., 2006) or difference equation models. 
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capita effective contact rate per-unit time (β) and the number of infectious individuals in 
the population (I) (Vynnycky and White, 2010).  
A susceptible individual can only acquire an infectious disease by entering into contact 
with an infectious individual. When this contact occurs the susceptible individual might 
or might not contract the disease. An effective contact rate (β) occurs when that contact 
would be sufficient to lead to an infection.  The β depends on the frequency of contacts 
between other individuals in a given group and the proportion of those contacts that are 
“effective” or sufficient to transmit the disease (Vynnycky and White, 2010).   
Mixing between individuals can be either homogeneous or heterogeneous. If 
homogeneous, individuals enter into contact with other individuals in proportion to the 
size of each group. However, when contacts are influenced by age or other 
characteristics, contact patterns are defined as “heterogeneous”. Both stochastic and 
deterministic models can be constructed using homogeneous or heterogeneous  
mixing (Vynnycky and White, 2010). 





III. Brief theoretical background on Discrete event simulation models 
 
Discrete event simulation (DES) originated within operational research theory (Pidd, 
2004) and is a continuous time model that employs a next event technique to control 
the behaviour of the model. The model only updates when a change of state occurs 
(Robinson, 2004). It is an individual level stochastic model as it tracks individual objects 
during the modelling using a random process.  
A simplistic definition can see DES as a system of queues and activities (Pidd, 2004; 
Brailsford and Hilton, 2001). The main elements of a DES model are the individual 
“entities” as these are the components being simulated and tracked. Entities can be a 
representation of individuals as would be the case in an infectious disease model. 
Attributes can be assigned to each entity, usually in the form of a label allowing the 
possibility of different outcomes at the individual level. Based on the value of the 
attributes, the entities transit through different activities that alter their characteristics 
and influence future events. Depending on the order and conditions of these activities, 
the entities can be held in queues until it is time to engage in another activity or expire 
(Brennan et al., 2006; Pidd, 2004; Brailsford and Hilton, 2001). In the context of 
infectious disease modelling, individuals can be held in queues to simulate periods of 
latency, infectiousness or when a patient has recovered. 
Entities can be organised into “classes” according to their attributes (such as age or 
gender) to engage in similar behaviour or to face similar conditions (Pidd, 2004). In the 
context of an infectious disease modelling the use of classes allows the possibility of 
heterogeneous mixing. 
DES models can also be constrained by “resources”. Resources are elements that are 
required for an activity to be undertaken. Therefore, within a health care context, a 
medical doctor may be required for a patient examination to occur, and thus the doctor 
would be represented as a resource. Although resources are not tracked in the same 
way as an entity, it is possible to record certain elements of their participation in the 
simulation process such as percentage of utilisation or time in the simulation.  
It is also possible to keep a record of the “countable” elements in the simulation. 
Compared with resources these countable elements are not used directly to process an 
activity; however, they can be used as inputs to aid or modify its results. In the context 
of infectious disease modelling, infectious or susceptible individuals can be 




The “activities” are processed in another element of the DES simulation referred to as a 
“work centre”. Within the work centre, code can be written to modify the attributes of 
the entities and to determine which future event will occur first. Interactions between 
individual entities can also be simulated within the code to determine whether a 
susceptible individual meets an infectious person and whether this contact resulted in a 
transmission of the disease. This interaction, coupled with the changes of state from 
susceptible to exposed and then to infectious allows for a dynamic estimation of an 
infectious disease.  
A DES model also employs a simulation clock that keeps track of the events within the 
model. The simulation determines the time of the next event and automatically jumps to 
that time. As such, there are no time cycles, although regular scheduled events can be 
coded to occur.   
As the model operates at an individual level and is stochastic the construction and 
running time might prove to be computationally expensive (Brennan et al., 2006; 





IV. Additional information relating the calibration of the ODE model 
Figure IV.1 and Figure IV.2 show the diagnostic plots of the 0.75 and 0.001 RR 
calibrations 







a) Trace plot b) Density and correlation plots 
  
































a) Trace plot b) Density and correlation plots 
 
 

























Figure IV.3 Spread of the pandemic by generational time: 1.3, 1.9 and 2.71 for the three RR scenarios (no vaccination) 
a) 0.75 reporting rate scenario 
GI: 1.3 GI: 1.9 (base case) GI: 2.7 
  
 
Lines in pink correspond to all age groups  
Lines in orange correspond to the 0-15 age group 
Lines in green olive correspond to the 16-39 age group 
Lines in green correspond to the 40-59 age group 
Lines in blue correspond to the 60 and over age group 




b) 0.01 reporting rate scenario 




Lines in pink correspond to all age groups  
Lines in orange correspond to the 0-15 age group 
Lines in green olive correspond to the 16-39 age group 
Lines in green correspond to the 40-59 age group 
Lines in blue correspond to the 60 and over age group 





c) 0.001 reporting rate scenario 
GI: 1.3 GI: 1.9 (base case) GI: 2.7 
 
  
Lines in pink correspond to all age groups  
Lines in orange correspond to the 0-15 age group 
Lines in green olive correspond to the 16-39 age group 
Lines in green correspond to the 40-59 age group 
Lines in blue correspond to the 60 and over age group 
the x-axis represents time, y-axis total number of notified cases; 
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V. Additional information regarding the CE of the vaccine intervention  
Table V.1, Table V.2 and Table V.3 provide additional information used to estimate the 
average wage loss per episode of A(H1N1) presented in Chapter 6, section 6.2.4 
Productivity losses. 
Table V.1 Daily wage during 2009 in Mexico 
Minimum wages per day Population under each wage 






Not specified 3,602,458 
Weighted average minimum wage per day $126.20 MXN 
Minimum wage per day in Mexico $54.80 
Total workforce in Mexico during 2009 was composed by 43,334,276 habitants.  
Information on 3,602,458 working individuals was not available  
The calculations excluded the not specified category and assumes that all people in each category receive 
the corresponding minimum wage  
Source: National Institute of Geography and Information (INEGI) 
Table V.2 Proportion of population at work per relevant age group 
Percentage of working 






14-29 (A) 31,353,019 13,831,158 0.441142781 
30-59 (B) 38,306,904 26,035,148 0.679646363 
60 and over (C) 9,087,542 3,461,936 0.380954058 
Letter in parenthesis used as a reference for the columns in this Table 
Table V.3 Productivity losses due to an A(H1N1) illness 
Age group 
Average 






working days in a 
month (F) 
Calculation  
(Row reference from Table 
V.2 and column reference 
from Table V.3Error! R
eference source not found.) 
Average wage 
loss per episode   
Lost wages for those who receive outpatient care 
14-29 
$126.20 5.00 0.714 
(A)*(D)*(E)*(F) $198.84 
30-59 (B)*(D)*(E)*(F) $306.34 
60 and over (C)*(D)*(E)*(F) $171.71 
Lost wage for those hospitalised 
14-29 
$126.20 5.30 0.714 
(A)*(D)*(E)*(F) $210.77 
30-59 (B)*(D)*(E)*(F) $324.72 
60 and over (C)*(D)*(E)*(F) $182.01 
Lost wage for those who required ICU care 
14-29 
$126.20 11.83 0.714 
(A)*(D)*(E)*(F) $470.46 
30-59 (B)*(D)*(E)*(F) $724.82 
60 and over (C)*(D)*(E)*(F) $406.27 
Letter in parenthesis used as a reference for the columns in this Table 






The information in Table V.4, Table V.5 and Table V.6 was used to estimate the 
outpatient costs of treatment shown in Chapter 6 Section 6.2.6.1 
 
Table V.4 Cost of oseltamivir  
Item Description Unit cost  
(MXN) 
Oseltamivir (A) One course of antiviral. Two tablets of Oseltamivir 75mg for 
five days for identified patients. One tablet per day for 10 




For three years and younger. One bottle presentation of 
12mg/ml in 100 ml. An average weight between 15 and 23 
kg is assumed. Doses of 45mg/day twice a day. 
The consumption of one whole package is assumed even if 
only a fraction is used. In this case, only 37% of the bottle is 
required. Cost per bottle 
$320.00 
Table V.5 Parameter estimations 
Parameter Description Value 
Proportion of 
children that had a 
consultation (0-3) 
(C) 
Estimated by dividing the number of lab-confirmed 
individuals in the 0-3 age group and the total number of 
lab-confirmed in the dataset. The daily database was 





Average family size in Mexico. Estimated with 
information obtained by the Institute of Statistics and 
Geography –INEGI- (INEGI, 2007) 
4.8 
Population at risk 
(E) 
Estimated by dividing the population at risk (estimated 
at 18.5  million by the MMH, above 36 months) by the 
population above 36 months (99.8 million from (INEGI, 
2007)) 
18.5% 
Proportion of ILI 
cases requiring 
antiviral (F) 
From Echevarría-Zuno et al. (2009)  75% 
 
Table V.6 Out-patient cost estimation 
Item Description Estimation 
(Row in Error! Reference source not f
ound. and Error! Reference source 
not found.) 
Unit cost (MXN) 
Oseltamivir 
Cost per adult 














$517 per consultation $1,034.00 










V.I Additional CE analysis graphs 
Figure V.1 and Figure V.2 contain the scatterplot of the 0.75 and 0.001 RR for the base 
case scenario.  
Figure V.1 Scatterplot: Base case scenario for the 0.75 RR scenario 
a) Population strategy 
 
 
b) Lab-confirmed strategy 
 
The black straight line represents the $110,000 threshold.  
Iterations to the right of the threshold line represents those where the vaccine intervention is cost-effective 
 
 
Figure V.2 Scatterplot: Base case scenario for the 0.001 RR scenario 
a) Population strategy 
 
 
b) Lab-confirmed strategy 
 
The black straight line represents the $110,000 threshold. Iterations to the right of the threshold lines represents those 








































































































Figure V.3 and Figure V.4 shows the scatterplot, CEAC and CEAF of the secondary 
analysis, where vaccines arrived 31 days later than anticipated for the 0.01 RR. Figure 
V.5 and Figure V.6 shows the scatterplot for the 0.75 and 0.001 RR scenario.  
Figure V.3 Scatterplot and CEAC: Secondary analysis for the 0.01 RR scenario 
a) Population strategy 
 
b) Lab-confirmed strategy 
 
The black straight line represents the $110,000 threshold. Dashed line represents the $330,000 threshold. 
 Iterations to the right of the threshold lines represents those where the vaccine intervention is cost-effective 
c) Population strategy 
 
d) Lab-confirmed strategy 
 
Black line: No vaccine strategy; Grey line: Vaccine strategy; Dashes line: $110,000 threshold; Dots and 
dashes line: $330,000 threshold. 































































































































Figure V.4 CEAF: Secondary analysis for the 0.01 RR scenario 
a) Population strategy 
 
b) Lab-confirmed strategy 
 
 
Figure V.5 Scatterplot: Secondary analysis for the RR of 0.75 
Scatter plot 
a) Population strategy 
 
b) Lab-confirmed strategy 
 
The black straight line represents the $110,000 threshold.  




























































































































Figure V.6 Scatterplot: Secondary analysis for the RR of 0.001 
 
a) Population strategy 
 
b) Lab-confirmed strategy 
 
The black straight line represents the $110,000 threshold.  
Iterations to the right of the threshold lines represents those where the vaccine intervention is cost-effective 
 
Figure V.7 Shows a comparison of the spread of the disease for the no-vaccine, 























































Figure V.7 Comparison between the no-vaccine, vaccination arriving as expected (primary analysis) and 31 days later (secondary analysis) 
for the lab-confirmed vaccine strategy 
a) 0.75 RR 
No vaccine Primary analysis Secondary analysis 
   
Lines in pink correspond to all age groups  
Lines in orange correspond to the 0-15 age group 
Lines in green olive correspond to the 16-39 age group 
Lines in green correspond to the 40-59 age group 
Lines in blue correspond to the 60 and over age group 





b) 0.01 RR 
No vaccine Primary analysis Secondary analysis 
   
Lines in pink correspond to all age groups  
Lines in orange correspond to the 0-15 age group 
Lines in green olive correspond to the 16-39 age group 
Lines in green correspond to the 40-59 age group 
Lines in blue correspond to the 60 and over age group 










c) 0.001 RR 
No vaccine Primary analysis Secondary analysis 
   
Lines in pink correspond to all age groups  
Lines in orange correspond to the 0-15 age group 
Lines in green olive correspond to the 16-39 age group 
Lines in green correspond to the 40-59 age group 
Lines in blue correspond to the 60 and over age group 





VI. Regional comparisons of methods to estimate the cost-effectiveness of 
vaccine interventions 
 
This appendix aims to describe the analysis performed on how often the type of 
approaches (static and dynamic) and methodologies (DTM, MM, sHybrid, sSim, dSim, 
etc.) are used around the world. This would be providing information on whether 
regions like Latin America (LA) (where Mexico resides) require increasing its 
awareness of more complex strategies to achieve better estimations of CE of infectious 
disease vaccine interventions. 
Section VI.I describe the methodology followed in the analysis and how the different 
retrieved articles were classified. Section VI.II provides a description of the results 
obtained, while section VI.III concludes with a summary of this appendix.  
 
VI.I Methodology  
A database was constructed, using the information retrieved from the analysis 
described in Chapter 35. The information retrieved was: type of methodology used; 
geographical setting; author location; year of publication; type of disease; and whether 
HI was incorporated,  
Articles were classified according to the country where the analysis was set 
(geographical location) and the location of the first author. A descriptive and regression 
analysis based on geographical and first author location, type of approached (static or 
dynamic) and year of publication was performed. 
Articles were then classified according to their country of origin. Countries were 
classified according to their gross domestic product (GDP) per capita on purchase-
power parity in 2012 (International Monetary Fund, 2017).  
The GDP per capita by region was calculated based on the GDP by country weighted 
by the number of papers produced. There were clear differences in GDP amongst 
Asian countries with Singapore, Hong Kong, Taiwan, Japan, Israel and South Korea 
having a much higher weighted GDP per capita ($38,606 current international dollars 
(CID)6) than Thailand, China, Indonesia, Philippines, India, Vietnam, Pakistan and 
Afghanistan ($5,280 CID). Accordingly, Asia was split into two regions: developed and 
                                               
5 Only on the information retrieved first search (excluding the update between 2010 and 2017). 
This was not updated as the focus of the corrections were focused on the ODE mode its 
calibration, the CE analysis and updating the main literature review described in Chapter 3. 
6 The current international dollars (CID) monetary units represent the same purchasing power (PPP) over 
the GDP as in the US dollar has in the United States (US)  (The World Bank, 2013). 
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non-developed. North America (NA) ($48,129 CID), Oceania ($41,386 CID), developed 
Asia ($38,606 CID) and Europe ($36,586 CID) were classified as regions with high 
GDP per capita. Latin America (LA) ($14,168 CID) was classified as a region with 
medium GDP per capita whilst non-developed Asia ($5,280 CID) and Africa ($3,994 
CID) were classified as regions with low GDP per capita.  
A logistic regression was performed to explore the relationship between the different 
GDP regions (grouped by geographical or author location) and the year of publication 
with whether the model was static or dynamic. The data was analysed using STATA 11 
(College Station, Texas 77845 USA®).  
 
VI.II Results  
VI.II.I Analysis by geographical region 
The identified articles evaluated the CE of a vaccine intervention in 57 different 
countries or regions. The majority were performed with the United States (US) followed 
by United Kingdom (UK) and Canada. Table VI.1, shows the countries in which the 
models were set, the total number of studies in each and the allocated geographical 
region. 




















Hungary 1 Europe 
UK 23 Europe 
European 
countries 

















Kenya 1 Africa 
Netherlands 15 Europe Japan 3 
Asia 
developed 
Lithuania 1 Europe 






















































Sweden 2 Europe Russia 1 Europe 







Colombia 5 Latin America Vietnam 2 
Asia non-
developed 


















1 Asia Venezuela 1 
Latin 
America 
Argentina 4 Latin America Austria 1 Europe West Africa 1 Africa 
Belgium 4 Europe 
Czech 
Republic 
1 Europe Zambia 1 Africa 




      
*Developed and Developing countries were classified as multiregional countries unless all countries considered pertain 
to a specific region such as Europe, LA or NA.  
 
Figure VI.1 shows that most articles described models set in Europe and North America 
(NA) (72%), with only 2% in Africa. Figure VI.2 shows the use of methodologies across 
geographical regions. More than 70% of the models use a static model in all the 
geographical region regions, the proportion increased to 100% for studies set in Africa 
and multiregional (MR) studies, 95% in developed Asia, 93% in non-developed Asia, 
92% in Oceania, 87% in NA, 77% in Europe and 74% in Latin America (LA). 
 

















Although the total number of studies using a dynamic approach was greater when the 
model was set in a European country (30 versus 15 and 7 in NA and LA respectively), 
LA had the biggest proportion of dynamic models (26%) compared with Europe (24%) 
and NA (13%). Oceania, non-developed Asia and developed Asia had 8%, 7%, 5%, 
respectively. No dynamic studies were set in Africa or in MRs (Figure VI.2). 
 
Figure VI.2 Static and dynamic models by geographical region 
 
 
If the systematic review retrieved all the published CE of vaccine interventions (within 
the analysed period), then it is possible to conclude that greatest number of dynamic 
studies were set in high GDP per-capita regions whilst the biggest proportion of 
dynamic based articles were set in middle GDP per-capita regions (Table VI.2). 
However, some articles were excluded due to lack of information or being written in a 
language that was not English or Spanish.  
 
Table VI.3Table VI.3 shows the results from the logistic regression when articles were 
classified according to geographical location and GDP per-capita. The setting of the 
model had no significant influence on the type of model chosen. It also shows that the 
use of dynamic models has increased over time; however, static models still 
















Static 95 97 20 13 20 12 10 6















Table VI.2 Regional setting by type of model 
Type of model 
GDP per-capita region 
High Medium Low Total 
Static 224 20 19 223 
83% 74% 95% 
Dynamic 46 7 1 54 
17% 26% 5% 
Total 270 27 20 317 
 
*MR studies were excluded from the GDP per-capita regional setting and type of model 
 
 
Table VI.3 Regression analysis: geographical region and type of approach  
Logistic regression: Static vs. Dynamic 
Model reference: Static 
Variable Odds ratio 
(95% CI) 
Published between 2006-2010 2.5 
(1.3-4.8) 
Reference: published before 2006 
Medium income GDP 1.3 
(0.5-3.2) 
Low income GDP 0.2 
(0.03-1.7) 
Reference: High-income GDP 
LR Chi2: 12.68 
p-value = 0.005* 
Pseudo R2= 0.043 





































































































































































































































































VI.II.II Comparison by type of model technique use 
 
The distribution of methods was dominated by DTM and MM in all regions (Europe, 
71%; NA, 78%; LA, 74%; Asia developed, 72%; Asia non-developed, 65%; Oceania, 
92% and Africa and MR, 81% combined). The most used dynamic model (SD) was 
used in 5 regions: Europe, 10%; NA, 5%; LA, 11%; Asia developed, 5% and Asia non-
developed, 7% (Table VI.4).  
Table VI.4 Methods used by regions 








Oceania Other* Total 
DTM 44 48 12 10 4 9 4 131 
 
35% 43% 44% 48% 29% 69% 25% 
 
MM 45 39 8 5 5 3 9 114 
 
36% 35% 30% 24% 36% 23% 56% 
 
SD 13 6 3 1 1 0 0 24 
 
10% 5% 11% 5% 7% 0% 0% 
 
sHybrid 5 7 0 5 2 0 2 21 
 
4% 6% 0% 24% 14% 0% 13% 
 
dHybrid 8 6 2 0 0 1 0 17 
 
6% 5% 7% 0% 0% 8% 0% 
 
dMM 5 1 2 0 0 0 0 8 
 
4% 1% 7% 0% 0% 0% 0% 
 
dSim 4 2 0 0 0 0 0 6 
 
3% 2% 0% 0% 0% 0% 0% 
 
iMM 1 2 0 0 2 0 1 6 
 
1% 2% 0% 0% 14% 0% 6% 
 
sSim 0 1 0 0 0 0 0 1 
 
0% 1% 0% 0% 0% 0% 0% 
 
Total 125 112 27 21 14 13 16 328 
 
100% 100% 100% 100% 100% 100% 100% 328 
 
Percentages relate to the total within the geographical region 
*Africa and Multiregional studies 
 
 
In terms of the preferred type of model when was static, the majority followed a DTM or 
MM approach (Figure VI.4). The SD, dHybrid, dMM approach was most used in Europe 







Figure VI.4 Type of static methodology used by geographical region 
 
*Africa and Multiregional 
 













sSim 0 1 0 0 0 0 0
iMM 1 2 0 0 2 0 1
Hybrid 5 7 0 5 2 0 2
MM 45 39 8 5 5 3 9




























dSim 4 2 0 0 0 0
dMM 5 1 2 0 0 0
dHybrid 8 6 2 0 0 1















VI.II.III Analysis by author location 
The 328 selected articles were produced by 242 different authors. The majority were 
based in Europe (41.3%) and NA (38.8%), whilst less than 1% resided in Africa. Only 
(42 (17%)) authors produced a dynamic model. Most of these were based in Europe 
(23 (55%)) and NA (14 (33%)) while only 4 (9.6%) resided in LA with 1 (2.4%) in 
Oceania. No authors using dynamic models were found in Asia (irrespective of 
development status) or Africa. 
Of the 29 dynamic models set in Europe (26 (90%)) were performed by a Europe-
based researcher. Similar numbers were found in NA where 86% (13 out of 15) were 
performed by an NA-based research, whilst in LA only 57% (4 out of 7) were performed 
by Latin America-based researchers. NA researchers performed most CE analysis in 
settings outside of their residence (38% of their total production). Europe-based authors 
only performed 7% of their dynamic models outside Europe. Authors in LA and Oceania 
did not produce any dynamic model outside their own region. 
Figure VI.6 shows the proportion of methodologies used by first author location.  The 
distribution is similar to the one shown in Figure VI.2. Most of the produced articles 
were performed using a static methodology regardless of author locations (more than 
70% in all regions).  
The number of dynamic studies was bigger in Europe and NA than in LA, but the 
proportion was very similar: 22%, 15% and 19% respectively.  
Out of the four articles published in Mexico, the only dynamic model was performed by 








Figure VI.6 Setting of static and dynamic models by author’s location 
 
 
Similar conclusions can be drawn as when analysing the frequency of dynamic models 
by setting. The greatest number of dynamic studies was performed by authors based in 
high GDP per-capita regions whilst the greatest proportion was performed by authors 
based in medium GDP per-capita regions (Table VI.5). 
 
Table VI.5 Authors location and type of models 
Type of model 
GDP per-capita region 
High Medium Low Total 
Static 250 17 6 273 
83% 81% 100%  
Dynamic 51 4 0 55 
17% 19% 0%  
Total 301 21 6 328 
 
The results of the logistic and multinomial logistic regression analysis (Table VI.6) show 
no statistically significant relation between the location of the first author and the type of 


















Static 100 118 17 21 4 11 2























Table VI.6 Regression analysis: author location and type of approach used 
Logistic regression: Static vs. Dynamic 
Reference: Static 
Variable Odds ratio 
(95% CI) 
Reference: published before 2006 
2006-2010 2.48 
(1.3-4.6) 




Reference: High-income GDP 
LR Chi2: 8.68 
p-value = 0.013* 
Pseudo R2= 0.029 
*Since no article using a dynamic model in a low GDP region, this region was combined with the low-medium GDP per-






VI.II.IV Comparison by type of modelling technique used 
Overall, the dominant type of method by author’s location was DTM and MM in all 
regions (Europe, 70%; NA, 72%; LA, 81%; Asia developed, 81%; Asia non-developed, 
100%, Oceania, 92% and Africa, 100%) (Figure VI.7 and Figure VI.8). 
 
Figure VI.7 Static methods used by author’s location 
 
 
When dynamic models were used, authors based in Europe, NA and LA preferred the 
SD approach, followed by the dHybrid approach. dSim were only performed by 
European and NA located authors. Authors located in Africa or Asia did not perform 
dynamic models (Figure VI.8). 
  






sSim 0 1 0 0 0 0 0
iMM 2 4 0 0 0 0 0
Hybrid 5 12 0 4 0 0 0
MM 44 49 8 7 2 2 2



















Europe North America Latin America Oceania
dSim 4 2 0 0
dMM 5 1 2 0
dHybrid 8 8 0 1

















The identified articles are evaluating the CE of a vaccine intervention in 57 different 
countries or regions. A large concentration of papers was performed with the US, UK 
and Canada as setting comprising 41% of the published articles. 
The greatest proportion of models followed a static approach in all geographical 
regions (60% or more). When analysing the proportion of articles by type of method 
used, most static models followed the DTM and MM techniques. When dynamic 
models were chosen, the preferred technique was SD. These conclusions were 
maintained when the analysis was made by author’s location. 
The number of dynamic models was greater in Europe that in NA or LA (30 versus 15 
and 7 respectively), however, LA had the biggest proportion of dynamic models (26% 
versus 24% in Europe and 13% in NA). 
The logistic regression when articles were classified according to geographical location 
and GDP per-capita showed that the setting of the model had no significant influence 
on the type of model chosen. Analyses showed that the frequency of dynamic model 
use has increased over time; however, static models still predominate. Similar results 
were obtained in the regression analysis when grouping by author’s location and GDP 
per-capita. 
Only four articles analysing the CE of a vaccine intervention were set in Mexico. Out of 
these, only one followed a dynamic approach. However, it was developed by an author 














VII. Literature review search filters 
 
VII.I Search filters used to identify the papers to explore the Cost-effectiveness 
of infectious disease vaccine interventions 
 
List of the more common keys used to construct search terms in the electronic 
databases are shown in this section (Glanville, et al. 2009, Scottish Intercollegiate 
Guidelines Network filter (SIGN), ISI Web of Knowledge, 2010). 
The cost effectiveness search filter was constructed using the brief version of the NHS 
Quality improvement Scotland filter, NHS Economic Evaluation Database filters (NHS 
EED) and the Scottish Intercollegiate Guidelines Network filter (SIGN). Additional 
search terms were added to capture any article published using Discrete Event 
Simulation and System dynamics methods. 
The remaining search filters were constructed based on the most relevant terminology 







Medline symbols  



















:  Truncation 
symbol 
  
.ti. Title .sh. Subject 
heading 
? wildcard   
.tw. Text word Adj Adjacent 
terms 























VII.II.I Costs effectiveness search filter  
1. Exp Economics/ 
2. Exp “cost and cost analysis”/ 
3. Quality of life/ 
4. Value of life/ 
5. Quality-adjusted life years/ 
6. Models, economics/ 
7. Markov chains/ 
8. Monte Carlo methods/ 
9.  Decision tree/ 
10. ec.fs. 
11. economics$.tw. 
12. (cost? or costing? or costly or costed).tw. 
13. (price? or pricing?).tw. 
14. (pharmacoeconomic? or (pharmaco adj economic?)).tw. 
15. Economics, pharmaceutical/ 
16. Budget$.tw. 
17. Expenditure$.tw. 
18. (value adj 1 (money or monetary)).tw. 
19. (fee or fees).tw. 
{198} 
 
20. “quality of life”.tw. 
21. qol$.tw 
22. hrqol$.tw. 
23. “Quality adjusted life years$”.tw. 






30. monte carlo.tw. 
31. (decision adj2 (tree$ or analys$ or model$)).tw. 
32. ((clinical or critical or patient) adj (path? or pathway?)).tw. 
33. (managed adj2 (care or network?)).tw. 
34. Discrete event simulation.mp. 
35. Computer simulation/ 
36. System dynamics.mp. 
37. or/1-36 




4. Vaccines, Inactivated 
5. Vaccines, Synthetic 
6. Viral Vaccines 
7. Vaccines, Combined 
8. Vaccines, Attenuated 
9. Vaccines, Acellular 
10. Vaccines, Conjugate 
11. Vaccines, Virosome 
12. Mass Vaccination/ 
13. Immunization, Secondary/ 
14. Booster.mp. 
15. Immunization Programs/ 








Exp Explode .tw. Text word $ Truncation 
symbol 
.af. All fields .sh. Subject 
subheading 
? wildcard 




.ti. Title .fs. Floating 
subheading 
/ A subject 
heading 
selected 
.mp. Free text search 
or search in the 
title, abstract 
and indexing 
Adj Adjacent terms or/ Combines 
search terms 
 
VII.III.I Cost effectiveness search filter 
1. exp health economics/ 
2. exp health care cost/ 
3. exp quality of life/ 
4. Economic$.tw. 
5. (cost? or costing? or costly or costed).tw. 
6. (price? or pricing?).tw. 
7. (pharmacoeconomics? or (pharmaco adj economic?)).tw. 
8. budget$.tw. 
9. expenditure$.tw. 
10. (value adj1 (money or monetary)).tw. 
11. (fee or fees).tw. 
12. "quality of life".tw. 
13. qol$.tw. 
14. hrqol$.tw. 







22. monte carlo.tw. 
23. (decision adj2 (tree$ or analys$ or model$)).tw. 
24. ((clinical or critical or patient) adj (path? or pathway?)).tw. 
25. (managed adj2 (care or network?)).tw. 
26. (value adj2 money).ti,ab. 
27. exp simulation/ 
28. computer simulation/ 
29. Discrete event simulation.mp. 




VII.III.II Vaccine search filter 
1. exp vaccination/ 
2. Booster.mp. 
3. Immunization/ 





VII.IV Econlit via Ovid 
 
Econlit symbols 




















.af. All fields .sh. Subject 
subheadin
g 








.ab. Abstract .hw.  Heading 
word 




.ti. Title .fs. Floating 
subheadin
g 
? wildcard   






VII.IV.I I.3.1 Costs effectiveness search filter  
1. Economics*.af. 
2. Cost effectiveness*.af. 
3. Cost utility*.af. 
4. Cost benefit*.af. 
5. Value of life.af. 
6. Quality-adjusted life years.af. 
7. "Quality of life*".af. 
8.  “Cost?*”.af. 
9. (cost? or costing? or costly or costed).tw. 
10. (cost adj analys?s*).af. 
11. (price? or pricing?).tw. 




16. (value adj 1 (money or monetary)).tw. 
17. (fee or fees).tw. 
18. qol$.tw 
19. hrqol$.tw. 







25. “Markov chains*”.af. 
26. “Decision tree*”.af. 
27. ec.af. 
28. “Monte Carlo*”.af. 
29. “Model*”.af. 
30. markov$.tw. 
31. monte carlo.tw. 
32. (decision adj2 (tree$ or analys$ or model$)).tw. 
33. ((clinical or critical or patient) adj (path? or pathway?)).tw. 
34. (managed adj2 (care or network?)).tw. 
35. Discrete event simulation* 
36. Computer simulation* 
37. System dynamics* 
38. or/1-37 









VII.V CINAHL  
 
CINAHL symbols 
MH Mayor subheading * Truncation symbol “” Look for a composed word 
“cost effectiveness” 
MM Exact mayor subject 
heading 
? wildcard   
+ Explode W  Within operator   
TI Title N Near operator   
TX Text word Adj Adjacent terms   
 
VII.V.I Costs effectiveness search filter  
1. (MH “Economics+”) 
2. (MH “Quality of life+”) 
3. (MM “Quality-Adjusted Life Years”) 
4. TX economic* 
5. TX Cost OR TX costing? or TX costly or TX costed 
6. TX price? or TX pricing* 
7. TX pharmacoeconomic? OR pharmaco W5 economic? OR TX pharma* W5 
economic* 
8. TX budget* 
9. TX expenditure* 
10. TX value N1 money OR monetary 
11. TX fee or fees 
12. TX quality of life 
13. TX qol* 
14. TX hrqol* 
15. TX qaly* 
16. TX Quality adjusted life year* 
17. TX cba 
18. TX cea 
19. TX cua 
20. TX utilit* 
21. TX markov* 
22. TX monte carlo 
23. TX decision W5 tree? OR analys* or model* 
24. TX clinical or critical or patient N5 path? Or pathway? 
25. TX managed N2 care or network? 
26. (MH “Cost and Cost Analysis+”) 
27. (MM “Cost benefit analysis”) 
28. TX cost utility 
29. TX Discrete event simulation 
30. TX Computer simulation 
{204} 
 
31. TX System dynamics 
32. or/1-31 
VII.V.II Vaccine search filter 
1. (MH “Vaccines+”) 
2. TX Vaccine*. 
3. (MH “Immunization+”) 






VII.VI Web of Knowledge 
 
Web of knowledge symbols 




VII.VI.I Costs effectiveness search filter  
1. Cost* 
2. Economic*  
3. Quality SAME life 
4. Cost* SAME analys?s 
5. Cost* SAME benefit 
6. Cost* SAME effectiveness 
7. Cost* SAME benefit 
8. Cost* SAME utility 
9. pharmacoeconomic* 
10. pharmaceutical SAME economic* 
11. decision SAME (tree OR analys?s) 
12. Markov SAME model 
13. Discrete Event Simulation OR DES 
14. Simulation SAME model 
15. System dynamics 
16. Dynamic SAME model* 
17. Computer simulation 
18. or/1-17 















TITLE Title W within 
TITLE-ABS Title or abstract search ? wildcard 
TITLE-
ABS-KEY 
Title, abstract or keyword search * Wildcard 
ABS Abstract search “” Look for a composed 
word “cost effectiveness” 
KEY Keyword search   
 
VII.VII.I Costs effectiveness search filter  
1. Cost 
2. Economic 
3. Quality W/2 life 
4. Cost W/5 analys?s 
5. cost W/2 benefit 
6. cost W/2 effectiveness 
7. cost W/2 benefit 
8. cost W/2 utility 
9. pharmacoeconomic* 
10. pharmaceutical W/5 economic* 
11. decision W/3 tree* 
12. decision W/3 analys?s 
13. Markov W/2 model 
14. Discrete Event Simulation  
15. Simulation W/5 model* 
16. System dynamics 
17. Dynamic* W/5 model* 
18. Computer simulation 
19. or/1-18 











VII.VII.III Health information resources  
 










Medline Web of Knowledge CINAHL Embase SCOPUS Econlit NHS EED 
1 Adenovirus 
• Adenoviridae/ 





• acute SAME respiratory 
SAME disease 
• Adenovirus 
• MM "Respiratory Distress 
Syndrome, Acute" 
• MM "Severe Acute 
Respiratory Syndrome”  
• MM "Respiratory Tract 
Diseases"  
• Adenovirus/ 
• Acute respiratory 
disease.mp.  





• Acute W/2 respiratory 
W/2 disease 
• Adenovirus.af. 




• Acute respiratory tract 
disease.af. 





• “Acute respiratory 
disease” 




• Diphtheria Toxoid/ 





• Diphtheria SAME Toxoid 
• Diphtheria SAME 
Antitoxin 
• Diphtheria SAME Toxin 
• MH “Diphtheria“ 
• MM “Diphtheria 
Antotoxin”  
• MH “Diphtheria Toxoid+” 
• Diphtheria antibody/  
•  Diphtheria toxin/  
•  Diphtheria/  
•  Diphtheria toxoid/  
•  Diphtheria vaccine/ 
• TITLE-ABS-
KEY(diphtheria) 











• MM "Haemophilus 
Influenzae" 
• MM "HIB Vaccine" 
• Haemophilus influenzae 
type b  
• MM "Influenza B Virus"  
• Haemophilus influenzae 
type b/  
• Haemophilus influenzae 
type b vaccine/ 
• TITLE-ABS-KEY 
(Haemophilus 
influenzae type b) 
•  





influenzae type b” 
• “Hib” 
4 
Hepatitis A virus 
(HAV) 
• Hepatitis A/ 
• Hepatitis A 
Antibodies/ 
• Hepatitis A virus/ 
• Hepatitis SAME A SAME 
Virus 
 
• MM "Hepatitis A" 
• MM "Hepatitis A 
Vaccines"  
• Hepatitis A/ 
• Hepatitis A.mp.  
 
• TITLE-ABS-
KEY(“Hepatitis A”)  
• "Hepatitis A".af. 
• HAV.mp. 






Hepatitis B virus 
(HBV) 
• Hepatitis B 
Antigens/ 
• Hepatitis B virus/ 
• Hepatitis B, 
Chronic/ 
• Hepatitis B/ 
• Hepatitis B Surface 
Antigens/ 
• HBV.mp. 
• Hepatitis SAME B SAME 
virus 
• MH "Hepatitis B+" 
• MM "Hepatitis B 
Vaccines" 
• MM "Hepatitis B, 
Chronic"  
• hepatitis B vaccine/  
• Hepatitis B/ 
• TITLE (“Hepatitis B”) • "Hepatitis B".af. 
• HBV.mp. 
• "Hepatitis B" 
• HBV 
6 
Hepatitis C virus 
(HCV) 
• Hepatitis C/ 
• HCV.mp. 
• Hepatitis SAME C SAME 
virus 
• MH "Hepatitis C+")  
• MM "Hepatitis C, Chronic" 
• Hepatitis C/  
• Hepatitis C virus/ 
• TITLE(“Hepatitis C”) • "Hepatitis C".af. 
• HCV.mp 










• Papillomavirus Infections 
• Papillomavirus 
• HPV 
• (MH "Papillomavirus 
Infections+")  
• (MM "Papillomaviruses")  
•  (MM "Papillomavirus 
vaccine”) 








8 Measles  
• Measles/ 
• Measles virus/ 
• Measles Vaccine/ 
• Measles.mp 
• Measles 
• Measles SAME virus 
• MH "Measles+" 
• (MH "Measles Vaccine+") 
• Measles vaccine/ 
•  Measles/  
• Measles vaccination/  
•  Measles virus/  
•  Measles antibody/ 
• TITLE (Measles) 
•  














•  SAME infection 
 
• (MM "Meningitis, 
Meningococcal")  
• (MH "Meningococcal 
Infections+")  













• Mumps virus/ 
• Mumps Vaccine/ 
• Mumps 
• Mumps SAME virus 
• MM "Mumps"  
• MH "Mumps Vaccine+" 
• Mumps vaccine/  
•  Mumps/  
• Mumps virus/ 






• Whooping Cough/ 
Pertussis 
Whooping Cough 
• MH "Pertussis Vaccine+"  
• MM "Whooping Cough"  
• Pertussis toxin/  
• Bordetella pertussis/  
•  Pertussis/  
•  Pertussis vaccine/ 
• TITLE(Pertussis) • Pertussis.af. • Pertussis 
12 Plague 
• Exp plague vaccine/ 





















• Pneumococcal SAME 
Infection* 




• (MM "Pneumococcal 
Infections")  























• MH "Poliomyelitis+"  • Poliomyelitis vaccine/  
•  Poliomyelitis virus 1/  
• Poliomyelitis virus/  
• Ppoliomyelitis/ 








• Rubella virus/ 
• Rubella Vaccine/ 
• Rubella.mp. 
• Rubella 
• Rubella SAME virus 
• (MH "Rubella+")  
• (MH "Rubella Vaccine+")  
• Rubella vaccine/ 
•  Rubella/  
• Rubella virus/ 
• Rubella antibody/ 
• TITLE(Rubella) • Rubella.af. • Rubella 
16 Tetanus 
• Tetanus/ 
• Tetanus Toxoid/ 
• Tetanus Toxin/ 
• Tetanus Antitoxin/ 
• Tetanus.mp. 
• Tetanus 
• Tetanus SAME toxoid 
• Tetanus SAME Antitoxin 
• (MM "Tetanus")  
• (MH "Tetanus Antitoxin+")  
• (MM "Tetanus Immune 
Globulin")  
• (MM "Tetanus Toxin")  
•  (MH "Tetanus Toxoid+") 
• Tetanus antibody/ 
• Tetanus/ 
• Tetanus toxin/ 
• Tetanus prophylaxis/ 
• Tetanus toxoid/ 
•  















• (MH "Tuberculosis+")  









18 Varicella  
• Chickenpox/ 





• (MM "Chickenpox 
Vaccine")  
• (MM "Chickenpox")  
•  Varicella 
• Chickenpox/ 







• Herpes Zoster.af. 
• Varicella 
• Chickenpox 
• Herpes Zoster 
Combined vaccines   







• No. 2 AND No.15 
• Diphtheria SAME Tetanus 
• DT 
• No. 2 AND No.16 
• "Diphtheria-Tetanus" • Diphtheria-Tetanus.mp. 





• No.2 AND No. 16  
• DT.af. 
• “Diphtheria Tetanus”.af. 












• No.2 AND No.11 
AND 15 
• Diphtheria SAME Tetanus 
SAME Pertussis 
• DTP 










• No.2 AND No.11 AND 














• No. 2 AND No. 5 
AND 11 AND 15 
• DTP SAME HBV 




• Diphtheria pertussis 
tetanus hepatitis B 
vaccine.mp. 
• Diphtheria pertussis 





• TITLE(dtp-“hepatitis b”)  
• TITLE(dtp-hbv) 
• No.2 AND No.5 AND 
No.11 AND No. 16 
• "Diphtheria Tetanus 
Pertussis Hepatitis B".af 
• "DTP-Hepatitis B".af. 
• "DTP-HBV".af. 
• Diphtheria AND 
Tetanus AND 







• No. 2 AND No.3 
AND No.11 AND 15 




• Diphtheria pertussis 
tetanus Haemophilus 








influenzae type b".af. 
• "DTP-Hib".af. 
• Diphtheria AND 
Tetanus AND 
Pertussis AND  
Haemophilus 






type b") OR TITLE-ABS-
KEY("DTP-Hib") 
• No.2 AND No.3 AND 
No.11 AND No. 16  






• No. 2 AND No.11 
AND No.13 AND 15 




• Diphtheria pertussis 
poliomyelitis tetanus 
Haemophilus influenzae 









• No.2 AND No.3 AND 
No.11 AND No. 14 AND 
No.16 
• (Diphtheria adj Tetanus 
adj Pertussis adj 
Haemophilus influenzae 
type b adj Polio).af. 
• DTP Hib Polio.af. 
 
• Diphtheria AND 
Tetanus AND 
Pertussis AND  
Haemophilus 
influenzae type b 
AND poli 
• DTP Hib Polio 
24 HAV-HVB 
• No. 4 AND No. 5 • No. 4 AND No. 5 • No. 4 AND No. 5 • Hepatitis A hepatitis B 
Vaccine.mp.  
• Hepatitis A hepatitis B 
vaccine/ 
• No. 5 AND No. 6 
• TITLE(“hav-hbv”) 
• No. 4 AND No.5 
 
• Hepatitis A Hepatitis 
B.af. 
• HAV HBV.af. 
• No.4 AND No.5 
 
• Hepatitis A AND 
Hepatitis B 
• “HAV HBV” 
25 HBV-Hib 
• No. 5 AND No. 3 • No. 5 AND No. 3 • No. 3 AND No. 5  • Hepatitis B 
Haemophilus influenzae 
type b Vaccine.mp.  
• Haemophilus influenzae 
type b hepatitis B 
vaccine/ 
• No. 3 AND No.5 
• TITLE(“hbv-hib”) 
• No.3 AND No. 5 
• No. 3 AND No. 5 • Hepatitis B AND 
Haemophilus 
influenzae type b 








• No 8 AND No. 10 
• Measles-Mumps 
• No 8 AND No. 10 




• No. 8 AND No.10 
 
• No. 8 AND No. 10 
• Measles-Mumps.af. 









• No 8 AND No. 10 
AND No.14 
• Measles SAME Mumps 
SAME Rubella  







•  TITLE("MMR") 





• No. 8 AND No. 10 AND 
No. 15 
 















• No. 1 AND No. 2 
AND 3 AND No.4 
• Measles SAME Mumps 
SAME Rubella SAME 
Varicella 




• Chickenpox measles 
mumps rubella 
vaccine.mp.  
• Chickenpox measles 





•  TITLE("MMRV") 
• No.8 AND No.10 AND 
No.15 AND No.18 
• Measles-Mumps-
Rubella-Varicella.af. 
• No. 8 AND No.10 AND 
No. 15 AND No. 18 








• Influenza search 
terms AND No. 12 
• Influenza search terms AND 
No. 13 
• Influenza search filter + 
No.13 
• Influenza search filter + 
No.13 
• Influenza Search Filters 
AND No. 13 
• Influenza Search filters 
AND No. 13 





• No. 12 AND No. 9 • No. 9 AND No. 13 • Pneumococcal  search 
filters + No. 9 
• Pneumococcal search 
filters + No. 9 
• Pneumococcal Search 
Filters AND No.9 
• Pneumococcal Search 
Filters AND No.9 






VII.IX References dataset 
No Author Year Method Disease 
1 A., Kuhlmann 2017 MM Pneumococcal 
2 Gerlier, L 2017 SD Influenza 
3 H., Christensen 2017 SD Meningococcal 
4 Largeron, Nathalie 2017 SD HPV 
5 M.J., Germar 2017 MM HPV 
6 N., Sundaram 2017 MM Pneumococcal 
7 P., Le 2017 MM Herpes 
8 L., Nagy 2016 SD Influenza 
9 A., Doroshenko 2016 dSim Pertussis 
10 A., Garcia 2016 MM Influenza 
11 Bar-Zeev, Naor 2016 DTM Rotavirus 
12 Blommaert, Adriaan 2016 MM Pneumococcal 
13 Boiron, L 2016 SD HPV 
14 Brisson, Marc 2016 dSim HPV 
15 C., Stoecker 2016 MM Pneumococcal 
16 C., Vargas Parada 2016 MM HPV 
17 D., Curran 2016 dHybrid HAV 
18 D., Setiawan 2016 MM HPV 
19 D., Yamin 2016 SD Rotavirus 
20 D., Zhao 2016 DTM Pneumococcal 
21 Durham, David P 2016 SD HPV 
22 E., Belchior 2016 MM Herpes 
23 E., Delgleize 2016 MM Pneumococcal 
24 E., Shim 2016 SD Influenza 
{215} 
 
25 H., Christensen 2016 dHybrid Meningococcal 
26 J.-F., Laprise 2016 dSim HPV 
27 K.A., Maurer 2016 MM Pneumococcal 
28 Kamiya, Hajime 2016 MM Tdap 
29 Lecocq, Heloise 2016 MM meningococcal 
30 Liu, Yi-Jun 2016 MM HPV 
31 Moodley, Nishila 2016 MM HIV 
32 Newall, A T 2016 MM Pneumococcal 
33 P., Chanthavilay 2016 SD HPV 
34 P., de Wals 2016 MM Meningococcal 
35 P.H., Le 2016 MM Herpes 
36 P.T., de Boer 2016 dHybrid Influenza 
37 R., Gasparini 2016 DTM Meningococcal 
38 S., Coretti 2016 MM Herpes 
39 Sartori, Ana Marli Christovam 2016 DTM Tadp 
40 Smith, Kenneth J 2016 MM Influenza 
41 Wu, David Bin-Chia 2016 MM Pneumococcal 
42 Wu, Joseph T 2016 DTM Enterovirus 
43 Y., Mousavi Jarrahi 2016 MM Rotavirus 
44 Aguilar, Ida Berenice Molina 2015 sSim HVP 
45 Ahmeti, Albana 2015 DTM Rotavirus 
46 Baguelin, Marc 2015 SD Influenza 
47 Burger, Emily A 2015 SD HPV 
48 Caldwell, Ronald 2015 DTM Pneumococcal 
49 Chit, Ayman 2015 
 
Influenza 
50 Chit, Ayman 2015 DTM Influenza 
51 Damm, Oliver 2015 dHybrid Influenza 
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52 de Soarez, Patricia Coelho 2015 MM Pneumococcal 
53 Dhankhar, Praveen 2015 SD HAV 
54 Diop, Abdou 2015 DTM Rotavirus 
55 Graham, Donna M 2015 MM HPV 
56 E.A., Burger 2015 dHybrid HPV 
57 Haasis, Manuel Alexander 2015 MM Pneumococcal 
58 Hoshi, Shu-ling 2015 MM Pneumococcal 
59 J.B., Ditkowsky 2015 MM Varicella 
60 Javanbakht, Mehdi 2015 DTM Rotavirus 
61 Jit, Mark 2015 SD HPV 
62 Kieninger, Martha Pena 2015 DTM Pneumococcal 
63 Komakhidze, T 2015 DTM Pneumococcal 
64 L.B., Connelly 2015 MM HPV 
65 Le, Phuc 2015 MM Hib 
66 Le, Phuc 2015 DTM Herpes 
67 Littlewood, Kavi J 2015 SD MMRV 
68 Mangen, Marie-Josee J 2015 MM Pneumococcal 
69 Marti, Sebastian Garcia 2015 MM Rotavirus 
70 Meeyai, Aronrag 2015 SD Influenza 
71 Meier, G 2015 MM Influenza 
72 Mezones-Holguin, Edward 2015 DTM Pneumococcal 
73 Mirelman, Andrew J 2015 MM Norovirus 
74 Novaes, Hillegonda Maria 2015 sSim HPV 
75 Owusu-Edusei, Kwame Jr 2015 SD Chlamydia 
76 Paternina-Caicedo, Angel 2015 DTM Rotavirus 
77 R.H., Doshi 2015 MM Routine immunization 
78 S., Shakerian 2015 DTM Rotavirus 
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79 S.-C., Chen 2015 dHybrid Influenza 
80 S.E.W., Puteh 2015 SD HPV 
81 Sibak, Mohammed 2015 DTM Pneumococcal 
82 Sigei, Charles 2015 DTM Rotavirus 
83 Thommes, Edward W 2015 SD Influenza 
84 Tirani, Marcello 2015 MM Meningitis 
85 Uruena, Analia 2015 DTM Rotavirus 
86 Vucina, V Visekruna 2015 DTM Pneumococcal 
87 Walwyn, Leslie 2015 sSim HPV 
88 Yin, Juan 2015 sHybrid HBV 
89 You, Joyce H S 2015 DTM Influenza 
90 Aidelsburger, Pamela 2014 MM Rotavirus 
91 Al Awaidy, Salah Thabit 2014 MM Rotavirus 
92 Alkoshi, Salem 2014 DTM Rotavirus 
93 Blakely, Tony 2014 MM HPV 
94 Bresse, Xavier 2014 SD HPV 
95 Chen, Jieling 2014 MM Pneumococcal 
96 Christensen, Hannah 2014 SD Meningitis 
97 Chui, Ka-Sing 2014 DTM Varicella 
98 Clements, Karen M 2014 DTM Influenza 
99 Ditkowsky, Jared B 2014 MM TBS 
100 Drolet, Melanie 2014 dSim HPV 
101 Freiesleben de Blasio, Birgitte 2014 SD Rotavirus 
102 Gomez, Jorge Alberto 2014 MM HPV 
103 Halder, Nilimesh 2014 dSim Pre-pandemic influenza 
104 Han, Kyu-Tae 2014 MM HPV 
105 Hoshi, Shu-ling 2014 MM Mumps 
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106 Isshiki, Takahiro 2014 DTM HPV 
107 Jia, Yuanxi 2014 sHybrid HBV 
108 Jiang, Yiling 2014 MM Pneumococcal 
109 Jit, Mark 2014 
 
HPV 
110 Kiatpongsan, Sorapop 2014 sSim HPV 
111 Knight, Gwenan M 2014 SD TBS 
112 L., Channing 2014 MM TB 
113 Laprise, Jean-Francois 2014 dSim HPV 
114 M., Khatibi 2014 DTM HPV 
115 Mezones-Holguin, Edward 2014 DTM Pneumococcal 
116 Newall, Anthony T 2014 SD Influenza 
117 Ordonez, Jaime E 2014 MM Pneumococcal 
118 Regnier, Stephane A 2014 MM Meningitis 
119 Rheingans, Richard 2014 DTM Rotavirus 
120 Suwantika, Auliya A 2014 sHybrid HAV 
121 Tu, Hong Anh T 2014 MM meningococcal 
122 Van Bellinghen, Laure-Anne 2014 MM Influenza 
123 Vemer, Pepijn 2014 DTM Pneumococcal 
124 You, Joyce H S 2014 MM Influenza 
125 Zhou, Fangjun 2014 DTM Imunization program 
126 A., Clark 2013 DTM HiB 
127 A., Paternina-Caicedo 2013 DTM Varicella 
128 Boccalini, Sara 2013 DTM Pneumococcal 
129 Chang, Wan-Chi 2013 DTM Rotavirus 
130 D.B.C., Wu 2013 DTM Pneumococcal 
131 Fonseca, Allex Jardim da 2013 MM HPV 
132 Gupta, Madhu 2013 MM Hib 
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133 Hepkema, Hiltsje 2013 MM Meningococcal 
134 Hoshi, Shu-ling 2013 MM Pneumococcal 
135 Itatani, Tomoya 2013 MM Pertussis 
136 J., Aponte-Gonzalez 2013 MM HPV 
137 J., Luttjeboer 2013 MM HPV 
138 K., Yamabe 2013 SD HPV 
139 Kim, JJ 2013 MM HPV 
140 Kim, JJ 2013 MM HPV 
141 Klok, Rogier M 2013 sHybrid Pneumococcal 
142 Kulpeng, Wantanee 2013 MM Pneumococcal 
143 M, Bakir 2013 DTM Rotavirus 
144 M., Gouveia 2013 MM Pneumococcal 
145 M., Gupta 2013 DTM Hib 
146 M., Hacimustafaoglu 2013 DTM Rotavirus 
147 Mamma, Maria 2013 DTM H1N1 
148 McGarry, Lisa J 2013 sHybrid Tdap 
149 N., Demarteau 2013 MM HPV 
150 P., Ayieko 2013 MM Pneumococcal 
151 P.T., de Boer 2013 MM Herpes 
152 Pitman, R J 2013 SD Influenza 
153 Pouwels, Koen B 2013 MM Meningococcal 
154 R., Itzler 2013 MM Rotavirus 
155 S.-C., Chen 2013 SD Influenza 
156 S.G., Marti 2013 MM Pneumococcal 
157 Stoecker, Charles 2013 MM Pneumococcal 
158 X., Bresse 2013 MM Herpes 
159 Y., Fu 2013 MM Pneumococcal 
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160 Kelso J 2013 dSim Pandemic influenza 
161 A.J., van Hoek 2012 SD Pneumococcal 
162 Atkins, Katherine E 2012 SD Rotavirus 
163 B.Y., Lee 2012 MM Influenza 
164 Baguelin, M 2012 SD Influenza 
165 Bilcke, Joke 2012 MM Herpes 
166 Blank, Patricia R 2012 DTM Pneumococcal 
167 Brydak, Lidia 2012 DTM Influenza 
168 By, Asa 2012 MM Pneumococcal 
169 C., Castaneda-Orjuela 2012 MM Pneumococcal 
170 Campos, Nicole G 2012 MM HPV 
171 Christovam Sartori, Ana Marli 2012 DTM Pneumococcal 
172 Coupe, Veerle M H 2012 iMM HPV 
173 Coyle, Doug 2012 MM Rotavirus 
174 D.N., Fisman 2012 MM Rotavirus 
175 D.R., Strutton 2012 MM Pneumococcal 
176 Demarteau, Nadia 2012 MM HPV 
177 Dempsey, Amanda F 2012 DTM Cytomegalovirus 
178 Earnshaw, Stephanie R 2012 sHybrid Pneumococcal 
179 Goldie, SJ 2012 iMM HPV 
180 Grzesiowski, Pawel 2012 MM Pneumococcal 
181 H.A.T., Tu 2012 DTM Rotavirus 
182 H.A.T., Tu 2012 MM HAV 
183 Hoshi, Shu-ling 2012 MM Pneumococcal 
184 J., Luyten 2012 MM HAV 
185 J.-E., Tarride 2012 DTM Influenza 
186 Jiang, Yiling 2012 MM Pneumococcal 
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187 K.J., Smith 2012 MM Pneumococcal 
188 Kawai, Kosuke 2012 SD HPV 
189 Knerer, Gerhart 2012 MM Pneumococcal 
190 Kuhlmann, Alexander 2012 MM Pneumococcal 
191 Lugner, AK 2012 SD Pandemic Influenza 
192 Moradi-Lakeh, Maziar 2012 DTM Hib 
193 Muangchana, Charung 2012 DTM Rotavirus 
194 N., Yamamoto 2012 MM HPV 
195 Patterson, Brian W 2012 MM Influenza 
196 Rozenbaum, Mark H 2012 SD Pertussis 
197 Sartori, Ana Marli C 2012 SD HAV 
198 Schaetti, Christian 2012 MM Cholera 
199 Schaetti, Christian 2012 MM Cholera 
200 Sharma, M 2012 iMM HPV 
201 Termrungruanglert, Wichai 2012 MM HPV 
202 van Hoek, Albert Jan 2012 MM Rotavirus 
203 van Hoek, AlJ 2012 SD Varicella 
204 Vanni, T 2012 dSim HPV 
205 Voko, Zoltan 2012 MM HPV 
206 Wu, David Bin-Chia 2012 SD Pneumococcal 
207 A., Perez-Rubio 2011 DTM Rotavirus 
208 Akin, Levent 2011 DTM Pneumococcal 
209 Alvis, Nelson 2011 MM Tetanus 
210 Babigumira, Joseph B 2011 SD Measles 
211 Bishai, David 2011 SD Measles 
212 Boccalini, Sara 2011 MM Pneumococcal 
213 Castaneda-Orjuela, Carlos 2011 DTM Pneumococcal 
{222} 
 
214 Chesson, Harrell W 2011 SD HPV 
215 Clements, Karen M 2011 DTM Influenza 
216 de Soarez, Patricia Coelho 2011 DTM Meningococcal 
217 Demarteau, Nadia 2011 MM HPV 
218 Gutierrez-Aguado, Alfonso 2011 MM HPV 
219 Hontelez, Jan A C 2011 dSim HIV 
220 J., Diez-Domingo 2011 DTM Pneumococcal 
221 Jit, Mark 2011 SD Rotavirus 
222 Lee, Vernon J 2011 MM HPV 
223 M.M., Touray 2011 
 
Pneumococcal 
224 Morano, Raul 2011 DTM Pneumococcal 
225 Mucino-Ortega, Emilio 2011 DTM Pneumococcal 
226 Nakamura, Mari M 2011 DTM Pneumococcal 
227 Newall, Anthony T 2011 MM Pneumococcal 
228 Praditsitthikorn, Naiyana 2011 MM HPV 
229 Prosser, Lisa A 2011 DTM H1N1 
230 R., Morano 2011 DTM Pneumococcal 
231 R.F., Itzler 2011 MM Rotavirus 
232 Robberstad, Bjarne 2011 MM Pneumococcal 
233 Rozenbaum, Mark H 2011 DTM Rotavirus 
234 Sato, Takanori 2011 MM Rotavirus 
235 Sato, Takanori 2011 MM Rotavirus 
236 Siddiqui, MR 2011 MM HBV 
237 Smith, Emily R 2011 DTM Rotavirus 
238 Szucs, Thomas D 2011 MM Herpes 
239 Takahashi, Kenzo 2011 DTM Measles 
240 Tilson, L 2011 SD Rotavirus 
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241 Tonolio Neto, Joao 2011 DTM Pneumococcal 
242 Tyo, Karen Richards 2011 MM Pneumococcal 
243 U.K., Griffiths 2011 DTM HiB 
244 Uruena, Analia 2011 DTM Pneumococcal 
245 V., Mogasale 2011 DTM Influenza 
246 Alvis, N. et al 2010 DTM Pneumococcal 
247 Alvis, N. et al 2010 MM Polio 
248 Baguelin, Marc. et al 2010 dHybrid H1N1 
249 Dasbach, E J. et al 2010 SD HPV 
250 Dee, A. et al 2010 MM HPV 
251 Demarteau, N. et al 2010 MM Cervical Cancer 
252 Dhankhar, P. et al 2010 DTM Pneumococcal 
253 Diaz, M. et al 2010 iMM HPV 
254 Giglio, N D. et al 2010 MM Pneumococcal 
255 Hutton, D W. et al 2010 sHybrid HBV 
256 Konno, R. et al 2010 MM Cervical Cancer 
257 Lee, B Y. et al 2010 DTM Pandemic Influenza 
258 Lee, B Y. et al 2010 DTM Influenza 
259 Liu, Pang-Hsiang. et al 2010 MM Cervical Cancer 
260 Mogasale, V. et al 2010 DTM Influenza 
261 Moore, L. et al 2010 MM Herpes zoster 
262 Newall, A T. et al 2010 dHybrid Pandemic Influenza 
263 Obradovic, M. et al 2010 MM HPV 
264 Olsen, Jens. et al 2010 dSim HPV 
265 Robin de Vries. et al 2010 dSim Pertussis 
266 Rozenbaum, M H. et al 2010 DTM Pneumococcal 
267 Rozenbaum, M H. et al 2010 DTM Pneumococcal 
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268 Rozenbaum, M H. et al 2010 DTM Pneumococcal 
269 Rubin, Jaime L. et al 2010 DTM Influenza 
270 Sander, B. et al 2010 dSim H1N1 
271 Smith, K J. et al 2010 MM Pneumococcal 
272 Sohn, Hyun Soon. et al 2010 DTM Pneumococcal 
273 Torvinen, S. et al 2010 MM HPV 
274 Vanagas, G. et al 2010 dMM HPV 
275 Westra, T A. et al 2010 DTM Pertussis 
276 Accetta, Gabriele 2010 MM HPV 
277 Berry, Stephen A 2010 DTM Rotavirus 
278 Giachetto Larraz, Gustavo 2010 MM Pneumococcal 
279 Giglio, N D 2010 MM Pneumococcal 
280 Iskedjian, Michael 2010 MM Pertussis 
281 Kim, Jane J 2010 MM HPV 
282 Kim, Sun-Young 2010 MM Rotavirus 
283 Kim, SY 2010 MM Pneumococcal 
284 L., Annemans 2010 MM Herpes 
285 Mangen, Marie-Josee J 2010 MM Rotavirus 
286 N.A., Guzman 2010 DTM Pneumococcal 
287 Sander, B 2010 dHybrid Influenza 
288 Annemans, L. et al 2009 MM HPV 
289 Anonychuk, Andrea M. et al 2009 dHybrid Cervical Cancer 
290 Atherly, D. et al 2009 MM HBV 
291 Banz K. et al 2009 dHybrid Varicella 
292 Beigi, R H. et al 2009 DTM Influenza 
293 Claes, C. et al 2009 MM Pneumococcal 
294 Clark, A D. et al 2009 DTM Rotavirus 
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295 Colantonio, L. et al 2009 MM Cervical Cancer 
296 Coudeville, L. et al 2009 SD Pertussis 
297 Coupe, V M H. et al 2009 MM HPV 
298 Dabral, M. et al 2009 DTM Measles 
299 De Kok, Inge M C M. et al 2009 MM HPV 
300 Gasparini, R. et al 2009 DTM HPV 
301 Ginsber, G M. et al 2009 MM Cervical Cancer 
302 Giorgi-Rossi, P. et al 2009 DTM Pneumococcal 
303 Hillemanns, P. et al 2009 MM HPV 
304 Hung, H F. et al 2009 sHybrid HBV 
305 Khazeni, N. et al 2009 dHybrid H1N1 
306 Khazeni, N. et al 2009 dHybrid Pandemic H5N1 
307 Kim, JJ. et al 2009 dHybrid HPV 
308 Kim, JJ. et al 2009 iMM HPV 
309 Kim, SY. et al 2009 sHybrid Rotavirus 
310 Lee, V J. et al 2009 DTM Pandemic Influenza 
311 Martin, A. et al 2009 MM Rotavirus 
312 Massad, E. et al 2009 SD HCV 
313 Mennini, F S. et al 2009 MM HPV 
314 Najafzadeh, M. et al 2009 sSim Herpes zoster 
315 O'Brien, M A. et al 2009 MM Otitis media 
316 Oddsson, K. et al 2009 MM HPV 
317 Poirier, B. et al 2009 DTM Pneumococcal 
318 Porras-Ramirez, A. et al 2009 DTM Influenza 
319 Ray, G T. et al 2009 DTM Pneumococcal 
320 Reynales-Shigematsu, LM. et al 2009 MM HPV 
321 Rogoza, R M. et al 2009 MM HPV 
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322 Rose, J. et al 2009 MM Rotavirus 
323 Sander, B. et al 2009 dSim Pandemic Influenza 
324 Schooling, C M. et al 2009 DTM Influenza 
325 Silfverdal, Sven Arne. Et al 2009 DTM Pneumococcal 
326 Sinanovic, E. et al 2009 MM Cervical Cancer 
327 Smith, K J. et al 2009 MM Pneumococcal 
328 Tediosi, F. et al 2009 dSim Malaria 
329 Thiry, N. et al 2009 MM HPV 
330 Van Hoek, A J. et al 2009 MM Herpes zoster 
331 Vespa, G. et al 2009 DTM Pneumococcal 
332 You, J H S. et al 2009 MM Pneumococcal 
333 Zahdi, M R. et al 2009 DTM HAV 
334 Zechmeister, I. et al 2009 dMM HPV 
335 Bergeron, C. et al 2008 MM HPV 
336 Bergman, A C S. et al 2008 MM Pneumococcal 
337 Bonanni, P. et al 2008 dHybrid Varicella 
338 Brisson, M. et al 2008 MM Herpes zoster 
339 Chesson, H W. et al 2008 DTM HPV 
340 Dasbach, E J. et al 2008 SD HPV 
341 Dasbach, E J. et al 2008 SD HPV 
342 Dasbach, E J. et al 2008 SD HPV 
343 Diaz, M. et al 2008 iMM HPV 
344 Goldhaber-Fiebert, J D. et al 2008 iMM HPV 
345 Goldie, S J. et al 2008 iMM HPV 
346 Gutierrez-Delgado, C. et al 2008 MM Cervical Cancer 
347 Jit, M. et al 2008 SD HPV 
348 Kim, JJ. et al 2008 dHybrid HPV 
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349 Kim, JJ. et al 2008 iMM HPV 
350 Kulasingam, S. et al 2008 MM HPV 
351 Largeron, N. et al 2008 MM HPV 
352 Lee, G M. et al 2008 MM Pertussis 
353 Lenne, X. et al 2008 MM HPV 
354 Lesley T. et al 2008 MM HBV 
355 Lloyd A. et al 2008 DTM Pneumococcal 
356 Luce, B R. et al 2008 DTM Influenza 
357 Newall, A T. et al 2008 DTM Influenza 
358 Ortega-Sanchez, I R. et al 2008 MM meningococcal 
359 Perez-Rubio, A. et al 2008 DTM Chinken Pox 
360 Prosser, L A. et al 2008 DTM Influenza 
361 Quezada, A. et al 2008 dMM HAV 
362 Rogoza, R M. et al 2008 sHybrid Cervical Cancer 
363 Schmier, J. et al 2008 DTM Influenza 
364 Shin, S. et al 2008 DTM HiB 
365 Sinha, A. et al 2008 DTM Pneumococcal 
366 Smith, K J. et al 2008 MM Pneumococcal 
367 Standaert, B et al 2008 MM Rotavirus 
368 Suarez, E. et al 2008 MM Cervical Cancer 
369 Szucs, T. et al 2008 MM HPV 
370 Tilson, L. et al 2008 MM HBV 
371 Tilson, L. et al 2008 MM Pneumococcal 
372 Usher, C. et al 2008 dSim HPV 
373 Valentim, J. et al 2008 SD Varicella 
374 Zhou, F J. et al 2008 DTM Varicella 
375 Zhuang, G H. et al 2008 MM HAV 
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376 Aballea, S. et al 2007 DTM Influenza 
377 Aballea, S. et al 2007 DTM Influenza 
378 Akumu, A O. et al 2007 MM HiB 
379 Armstrong, G L. et al 2007 MM HAV 
380 Bauch, C T. et al 2007 SD HAV 
381 Brisson, M. et al 2007 MM HPV 
382 Broughton, E I. et al 2007 DTM HiB 
383 De Wals, P. et al 2007 dMM meningococcal 
384 Elamin H. E. et al 2007 SD HPV 
385 Ellis, A. et al 2007 MM HAV 
386 Evers, S. et al 2007 DTM Pneumococcal 
387 Goldie, S J. et al 2007 dHybrid HPV 
388 Hammerschmidt, T. et al 2007 dHybrid Varicella 
389 Hibbert, C L. et al 2007 DTM Influenza 
390 Hoshi, S L. et al 2007 DTM Influenza 
391 Hutton, D W. et al 2007 sHybrid HBV 
392 Insinga, R P. et al 2007 SD HPV 
393 Jakiche, R. et al 2007 DTM HAV/HBV/HCV 
394 Kim, JJ. et al 2007 dHybrid HPV 
395 Kulasingam, S. et al 2007 MM HPV 
396 Lee, G M. et al 2007 MM Pertussis 
397 Lopez, E. et al 2007 dMM HAV 
398 Marchetti, M. et al 2007 sHybrid Influenza 
399 Merito, M. et al 2007 MM Pneumococcal 
400 Navas, E. et al 2007 DTM Influenza 
401 Neilson, A R. et al 2007 dMM HPV 
402 Pellissier, J M. et al 2007 MM Herpes zoster 
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403 Rein, D B. et al 2007 MM HAV 
404 Rheingans, R D. et al 2007 DTM Rotavirus 
405 Rothberg, M B. et al 2007 MM Herpes zoster 
406 Sinha, A. et al 2007 DTM Pneumococcal 
407 Thompson, K M. et al 2007 SD Polio 
408 Widdowson, Marc-Alain. et al 2007 MM Rotavirus 
409 Alvis, N. et al 2006 DTM HiB 
410 Baio, G. et al 2006 MM Influenza 
411 Cai, Li. et al 2006 DTM Influenza 
412 Guzmán, N A. et al 2006 DTM HiB 
413 Hornberger, J. et al 2006 MM Herpes zoster 
414 Lenne, X. et al 2006 SD Varicella 
415 Maciosek, M V. et al 2006 DTM Influenza 
416 Martin-Fernandez, J. et al 2006 DTM Influenza 
417 Platonov, A E. et al 2006 DTM HiB 
418 Prosser, L A. et al 2006 DTM Influenza 
419 Ray, G T. et al 2006 DTM Pneumococcal 
420 Salo, H. et al 2006 DTM Influenza 
421 Skowronski, D M. et al 2006 DTM Influenza 
422 Trotter, C L. et al 2006 SD meningococcal 
423 Turner, D A 2006 DTM Influenza 
424 Vijayaraghavan, M. et al 2006 MM Measles 
425 Wisloff, T. et al 2006 MM Pneumococcal 
426 Caro, J Jaime. Et al 2005 MM Pertussis 
427 Chodick, G. et al 2005 sHybrid Varicella 
428 Goldman, G S 2005 MM Varicella 
429 Griffiths, U K. et al 2005 MM HBV 
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430 Gutierrez, J P t al 2005 DTM Influenza 
431 Iskedjian, M. et al 2005 MM Pertussis 
432 Krahn, M. et al 2005 MM HCV 
433 Mangtani, P. et al 2005 MM Pneumococcal 
434 Marchetti, M. et al 2005 MM Pneumococcal 
435 McIntosh, E. et al 2005 DTM Pneumococcal 
436 Meltzer M. et al 2005 DTM Influenza 
437 Navas, E. et al 2005 DTM Pneumococcal 
438 Rothberg, M B. et al 2005 sHybrid HBV 
439 Salo, H. et al 2005 MM Pneumococcal 
440 Shepard, CW. et al 2005 DTM meningococcal 
441 Tseng, H F. et al 2005 DTM Varicella 
442 Valenzuela, M T. et al 2005 MM HAV 
443 Vimolket, T. et al 2005 DTM HBV 
444 Zhou, F J. et al 2005 DTM 
diphtheria/tetanus toxoids/acellular pertussis; 
tetanus/diphtheria toxoids; HiB conjugate; inactivated 
poliovirus; measles/mumps/rubella; HBV; varicella vaccines 
445 Al V. Taira. et al 2004 dHybrid HPV 
446 Butler, J R G. et al 2004 DTM Pneumococcal 
447 Coudeville, L. et al 2004 dMM Varicella 
448 Dayan, G H. et al 2004 DTM Measles 
449 De Wals, P. et al 2004 MM meningococcal 
450 De Wals, P. et al 2004 MM meningococcal 
451 Goldie, S J. et al 2004 MM HPV 
452 Griffiths, U K. et al 2004 MM Tetanus 
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453 Iskedjian, M. et al 2004 MM Pertussis 
454 Jacobs, R J. et al 2004 MM HBV 
455 Melegaro, A. et al 2004 MM Pneumococcal 
456 Peña-Rey, I. et al 2004 DTM Varicella 
457 Postma, M J. et al 2004 DTM HAV 
458 Purdy, K W. et al 2004 MM Pertussis 
459 Scuffham, P A. et al 2004 MM Pertussis 
460 Thiry, N. et al 2004 sHybrid Varicella 
461 Welte, R. et al 2004 DTM meningococcal 
462 Zhou, F J. et al 2004 DTM Mumps/Rubella 
463 Aggarwal, R. et al 2003 MM HBV 
464 Banz K. et al 2003 dHybrid Varicella 
465 Bos, J M. et al 2003 DTM Pneumococcal 
466 Brisson, M. et al 2003 SD Varicella 
467 Claes, C. et al 2003 MM Pneumococcal 
468 Ess, S M. et al 2003 DTM Pneumococcal 
469 Hanslik, T. et al 2003 DTM Varicella 
470 Hersh, A L. et al 2003 MM BCG 
471 Hsu, H C. et al 2003 MM Chinken Pox 
472 Jaccard Ruedin, H. et al 2003 DTM Pneumococcal/Meningococal 
473 Jacobs, R J. et al 2003 MM HAV/HBV 
474 Jacobs, R J. et al 2003 MM HAV 
475 Kulasingam, S. et al 2003 MM HPV 
476 Lebel, Marc H. et al 2003 sHybrid Pneumococcal 
477 McIntosh, E. et al 2003 DTM Pneumococcal 
478 Péchevis, M. et al 2003 DTM HAV 
479 Rancourt, C. et al 2003 DTM meningococcal 
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480 Ruedin, H Jaccard. Et al 2003 DTM Pneumococcal/Meningococal 
481 Sanders, GD. et al 2003 sHybrid HPV 
482 Sisk JE. et al 2003 MM Pneumococcal 
483 Banz K. et al 2002 dHybrid Varicella 
484 Brisson, M. et al 2002 SD Varicella 
485 Chodick, G. et al 2002 sHybrid HAV 
486 Das Gupta, R. et al 2002 DTM Influenza 
487 Edmunds, W J. et al 2002 dHybrid Pertussis 
488 Getsios, D. et al 2002 DTM Varicella 
489 Pepper, P V. et al 2002 sHybrid Pneumococcal 
490 Pisu, M. et al 2002 DTM HBV 
491 Plans, P. et al 2002 DTM Pneumococcal 
492 Rothberg, M B. et al 2002 MM Varicella 
493 Scott RD II. et al 2002 DTM meningococcal 
494 Stevenson, M. et al 2002 dMM Pertussis 
495 Teppakdee, A. et al 2002 MM HAV 
496 Trotter, C L. et al 2002 DTM meningococcal 
497 Wutzler, P. et al 2002 SD Varicella 
498 Zhou, F J. et al 2002 DTM HiB 
499 Bos, J M. et al 2001 DTM meningococcal 
500 Chodick, G. et al 2001 sHybrid HAV 
501 Dayan, G H. et al 2001 DTM Influenza 
502 Diel, R. et al 2001 MM HAV 
503 Du Chatelet, I P. et al 2001 DTM meningococcal 
504 Edmunds, W J. et al 2001 MM Herpes zoster 
505 Fitzner, K A. et al 2001 DTM Influenza 
506 Ginsber, G M. et al 2001 MM HAV 
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507 Harris, A. et al 2001 MM HAV 
508 Iskedjian, M. et al 2001 DTM Pertussis 
509 Jacobs, R J. et al 2001 DTM HAV/Varicella/Pneumococcal 
510 Limcangco, M R. et al 2001 DTM HiB 
511 Luce, B R. et al 2001 DTM Influenza 
512 Meltzer M. et al 2001 DTM HAV 
513 Muennig, P A. et al 2001 DTM Influenza 
514 Pokorn, M. et al 2001 DTM HiB 
515 Postma, M J. et al 2001 MM Pneumococcal 
516 Skull, S A. et al 2001 DTM meningococcal 
517 Skull, S A. et al 2001 DTM meningococcal 
518 Tucker, A W. et al 2001 DTM Polio 
519 Weaver, M. et al 2001 DTM Pneumococcal/Influenza 
520 Ament, A. et al 2000 DTM Pneumococcal 
521 De Graeve, D. et al 2000 DTM Pneumococcal 
522 Forcen, T. et al 2000 sHybrid Chinken Pox 
523 Gessner, B D. et al 2000 DTM Respiratory syncytal virus 
524 Hyer, R N. et al 2000 DTM Adenovirus 
525 Jacobs, R J. et al 2000 DTM HAV 
526 Lieu, T A. et al 2000 sHybrid Pneumococcal 
527 Pepper, P V. et al 2000 sHybrid Pneumococcal 
528 Rajan, E. et al 2000 DTM HAV 
529 Saab, S. et al 2000 DTM HAV 
530 Sisk JE. et al 2000 MM Pneumococcal 
531 Smith, K J. et al 2000 MM Chinken Pox 
532 Szucs, T. et al 2000 DTM HAV/HBV 
533 Weycker, D. et al 2000 DTM Otitis media 
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534 Zurn, P. et al 2000 DTM HBV 
535 Barry O'Connor, J. et al 1999 MM HAV 
536 Beutels, P. et al 1999 MM Pertussis 
537 Bovier, P A. et al 1999 MM meningococcal 
538 Coudeville, L. et al 1999 SD Varicella 
539 Das, A. et al 1999 sHybrid HAV 
540 Deuson, R R. et al 1999 DTM HBV 
541 Domingo, J D. et al 1999 sHybrid Varicella 
542 Fendrick, A M. et al 1999 sHybrid HiB/HBV 
543 Pathania, V S, et al 1999 SD BCG 
544 Postma, M J. et al 1999 DTM Influenza 
545 Scuffham, P A. et al 1999 DTM Varicella 
546 Scuffham, P A. et al 1999 DTM Varicella 
547 Howell, M R. et al 1998 DTM Adenovirus 
548 Krahn, M. et al 1998 MM HBV 
549 Pelletier, L. et al 1998 SD Measles 
550 Shiell, A. et al 1998 DTM Measles 
551 Smith, W J. et al 1998 DTM Chinken Pox 
552 Tormans, G. et al 1998 MM Pertussis 
553 Arnal, J M. et al 1997 sHybrid HAV 
554 Baltussen, R. et al 1997 DTM Pneumococcal 
555 Garuz, R. et al 1997 dHybrid HBV 
556 Gray, A M. et al 1997 DTM Varicella 
557 Nettleman, M D. et al 1997 MM Varicella 
558 Smith, S. et al 1997 MM HAV 
559 Beutels, P. et al 1996 MM Varicella 
560 Fenn, P. et al 1996 MM HBV 
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561 JR, WILLIAMS 1996 SD HBV 
562 Miller, M A. et al 1996 DTM Polio 
563 Williams, J R. et al 1996 SD HBV 
564 Antonanzas, F. et al 1995 MM HBV 
565 Jackson, L A. et al 1995 DTM meningococcal 
566 Lieu, T A. et al 1995 DTM Varicella 
567 Margolis, H S. et al 1995 DTM HBV 
568 Shepard, DS. et al 1995 MM Measles/tetanus/typhoid/HBV/DTP 
569 Van Damme, P. et al 1995 DTM HBV 
570 Huse, D M. et al 1994 MM Pneumococcal 
571 Lieu, T A. et al 1994 SD Varicella 
572 Levine, O S. et al 1993 MM HiB 
573 Tormans, G. et al 1993 DTM HBV 
574 Vittorio D. et al 1993 MM HBV 
575 Antonanzas, F. et al 1992 DTM HBV 
576 Ginsber, G M. et al 1992 DTM HBV 
577 Ginsber, G M. et al 1992 DTM HBV 
578 Fernandez B R. et al 1991 DTM HBV 
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